Patient Education Brochure

Please see Important Safety Information on pages 6-13 and accompanying full
Prescribing Information for TAFINLAR, including Medication Guide, and full Prescribing
Information for MEKINIST, including Patient Information Leaflet, in back pocket.
Table of contents
Contents
Introduction---------------------------------------------------------------------------------- 4
Side effects tips --------------------------------------------- 20
Getting started ------------------------------------------------ 5
What are some tips that may help me with certain side effects? ------------------20
What is metastatic melanoma? ---------------------------------------------------------- 5
Side effects calendar ----------------------------------------------------------------------24
What is the combination of TAFINLAR + MEKINIST? --------------------------------- 5
Resources------------------------------------------------------ 26
Important Safety Information for TAFINLAR and MEKINIST
when used in combination -------------------------------------------------------------------- 6
Partnering with your healthcare team --------------------------------------------------26
What should I tell my healthcare provider before starting treatment? ------------14
General information about TAFINLAR + MEKINIST in combination ---------------30
Taking your medicines ------------------------------------ 16
Glossary -------------------------------------------------------------------------------------31
How should I take TAFINLAR + MEKINIST in combination? ------------------------16
Notes-----------------------------------------------------------------------------------------32
Patient support resources-----------------------------------------------------------------27
Tips to help you remember to take TAFINLAR + MEKINIST -------------------------19
Turn to page 31 for a glossary of helpful terms.
2
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
3
Introduction
This guide is meant to help you and your loved ones understand your treatment
with TAFINLAR + MEKINIST in combination, and partner with your healthcare
providers, who include doctors, nurses, and pharmacists.
Remember that friends, family members, and caregivers can be a great source of
support during visits to healthcare providers. Don’t hesitate to talk openly during
these visits and ask any questions you may have. Your healthcare team is there to
help you in any way possible.
It’s important to build relationships with your
healthcare providers. Don’t hesitate to ask them
any questions you have during treatment.
You can use the space below to keep track of
members of your support team and to record their
key information:
What is metastatic melanoma?
Melanoma is a type of skin cancer that begins in the cells that give skin its color
(melanocytes). Metastatic melanoma occurs when melanoma cells spread to other
parts of the body.
Getting started
Receiving a cancer diagnosis and starting new medicines may bring a wide range
of emotions.
GETTING STARTED
NOTES
What is the combination of
TAFINLAR + MEKINIST?
TAFINLAR + MEKINIST are prescription medicines that can be used in combination
to treat people with a type of skin cancer called melanoma:
• That has spread to other parts of the body (metastatic) or cannot be removed
by surgery (unresectable), and
• That has a certain type of abnormal “BRAF” (V600E or V600K mutationpositive) gene.
TAFINLAR in combination with MEKINIST is not used to treat people with a type of
skin cancer called wild-type BRAF melanoma.
Your healthcare provider will perform a test to make sure that TAFINLAR + MEKINIST
in combination is right for you.
It is not known if TAFINLAR + MEKINIST in combination is safe and effective in children.
TAFINLAR and MEKINIST target two different points in a pathway that sends signals
in cells. TAFINLAR + MEKINIST in combination may slow the growth of certain
melanoma cancer cells.
4
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
33
5
GETTING STARTED (cont’d)
Important Safety Information for
TAFINLAR and MEKINIST when
used in combination
TAFINLAR® (dabrafenib) 50 mg, 75 mg capsules
MEKINIST® (trametinib) 0.5 mg, 1 mg, 2 mg tablets
TAFINLAR may cause serious side effects, including risks of new cancers:
TAFINLAR, when used in combination with MEKINIST, may cause a type of skin
cancer called cutaneous squamous cell carcinoma (cuSCC). New melanoma lesions
have also occurred in people who take TAFINLAR. TAFINLAR and MEKINIST in
combination may cause new cancers, including basal cell carcinoma. Talk with your
healthcare provider about your risk for these cancers.
Check your skin and tell your healthcare provider right away about
any skin changes, including a:
• new wart
• skin sore or reddish bump that bleeds or does not heal
• change in size or color of a mole
TAFINLAR and MEKINIST in combination may cause serious side
effects, including:
Bleeding problems
TAFINLAR and MEKINIST in combination can cause serious bleeding problems, especially
in your brain or stomach, and can lead to death. Call your healthcare provider and get
medical help right away if you have any unusual signs of bleeding, including:
• headaches, dizziness, or feeling weak
• coughing up blood or blood clots
• vomiting blood or your vomit looks like “coffee grounds”
• red or black stools that look like tar
Blood clots
TAFINLAR and MEKINIST in combination can cause blood clots in your arms or
legs, which can travel to your lungs and can lead to death. Get medical help
right away if you have the following symptoms:
• chest pain
• sudden shortness of breath or trouble breathing
• pain in your legs with or without swelling
• swelling in your arms or legs
• a cool or pale arm or leg
Your healthcare provider should check your skin before you start taking
TAFINLAR, and every 2 months while taking TAFINLAR, to look for any new skin
cancers. Your healthcare provider may continue to check your skin for 6 months
after you stop taking TAFINLAR.
Your healthcare provider should also check for cancers that may not occur on the
skin. Tell your healthcare provider about any new symptoms that have developed
while taking TAFINLAR and MEKINIST in combination.
6
Please see accompanying full Prescribing Information for TAFINLAR, including
Medication Guide, and full Prescribing Information for MEKINIST, including
Patient Information Leaflet.
7
GETTING STARTED (cont’d)
Important Safety Information for
TAFINLAR and MEKINIST when used
in combination (cont’d)
Heart problems, including heart failure
Your healthcare provider should check your heart function before you start taking
TAFINLAR and MEKINIST in combination and during treatment. Call your
healthcare provider right away if you have any of the following signs and
symptoms of a heart problem:
•
•
•
•
feeling like your heart is pounding or racing
shortness of breath
swelling of your ankles and feet
feeling lightheaded
Eye problems
TAFINLAR and MEKINIST in combination can cause severe eye problems that can
lead to blindness. Call your healthcare provider right away if you get these
symptoms of eye problems:
• blurred vision, loss of vision, or other vision changes
• seeing color dots
• halo (seeing blurred outline around objects)
• eye pain, swelling, or redness
Fever
TAFINLAR and MEKINIST in combination can cause fever, which may be serious. When
taking TAFINLAR and MEKINIST in combination, fever may happen often or may be
severe. In some cases, chills or shaking chills, too much fluid loss (dehydration), low
blood pressure, dizziness, or kidney problems may happen with the fever. Call your
healthcare provider right away if you get a fever while taking TAFINLAR or MEKINIST.
Skin reactions
Rash and other skin reactions are a common side effect of TAFINLAR and MEKINIST
in combination. In some cases these rashes and other skin reactions can be severe,
and may need to be treated in a hospital. Call your healthcare provider if you get
any of the following symptoms:
• skin rash that bothers you or does not go away
• acne
• redness, swelling, peeling, or tenderness of hands or feet
• skin redness
Increased blood sugar (hyperglycemia)
Some people may develop high blood sugar or worsening diabetes during treatment
with TAFINLAR and MEKINIST in combination. If you are diabetic, your healthcare
provider should check your blood sugar levels closely during treatment with TAFINLAR
and MEKINIST. Your diabetes medicine may need to be changed. Tell your healthcare
provider if you have any of the following symptoms of severe high blood sugar:
• increased thirst
• urinating more often than normal, or urinating an increased amount of urine
Lung or breathing problems
Tell your healthcare provider if you have any new or worsening symptoms of lung
or breathing problems, including:
• shortness of breath
• cough
8
Please see accompanying full Prescribing Information for TAFINLAR, including
Medication Guide, and full Prescribing Information for MEKINIST, including
Patient Information Leaflet.
9
GETTING STARTED (cont’d)
Important Safety Information for
TAFINLAR and MEKINIST when used
in combination (cont’d)
TAFINLAR may cause healthy red blood cells to break down too early in
people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This
may lead to a type of anemia called hemolytic anemia, where the body does not
have enough healthy red blood cells. Tell your healthcare provider if you have any
of the following signs or symptoms of anemia or breakdown of red blood cells:
• yellow skin (jaundice)
• weakness or dizziness
• shortness of breath
TAFINLAR and MEKINIST in combination may harm your unborn baby.
Females who are able to become pregnant should use birth control (contraception)
during treatment with TAFINLAR and MEKINIST in combination and for 4 months
after stopping treatment with TAFINLAR and MEKINIST.
Birth control using hormones (such as birth control pills, injections, or patches) may
not work as well while you are taking TAFINLAR and MEKINIST in combination. You
should use another effective method of birth control while taking TAFINLAR and
MEKINIST in combination.
Talk to your healthcare provider about birth control methods that may be right
for you during this time.
Tell your healthcare provider right away if you become pregnant during
treatment with TAFINLAR and MEKINIST in combination.
10
Please see accompanying full Prescribing Information for TAFINLAR, including
Medication Guide, and full Prescribing Information for MEKINIST, including
Patient Information Leaflet.
Common side effects of TAFINLAR and MEKINIST when used in
combination include:
• tiredness
• nausea or vomiting
• stomach-area (abdominal) pain
• diarrhea
• cough
• swelling of the face, arms, or legs
• headache
• night sweats
• decreased appetite
• constipation
• muscle or joint aches
Other side effects
Fertility problems
TAFINLAR and MEKINIST in combination may cause fertility problems in females.
This could affect your ability to become pregnant. Talk to your healthcare
provider if this is a concern for you.
Low sperm counts
TAFINLAR may cause lower sperm counts in males. This could affect the ability to
father a child. Talk to your healthcare provider if this is a concern for you.
Nursing mothers
It is not known if TAFINLAR and/or MEKINIST passes into your breast milk. You
and your healthcare provider should decide if you will take TAFINLAR and
MEKINIST or breastfeed. You should not do both.
11
GETTING STARTED (cont’d)
Important Safety Information for
TAFINLAR and MEKINIST when used
in combination (cont’d)
New or worsening high blood pressure (hypertension)
Your healthcare provider should check your blood pressure during treatment with
MEKINIST. Call your healthcare provider right away if you develop high blood
pressure, your blood pressure worsens, or you have severe headache,
lightheadedness, or dizziness.
These are not all of the possible side effects of TAFINLAR and MEKINIST,
alone and in combination. For more information about side effects, ask
your healthcare provider or pharmacist.
Before you take TAFINLAR and MEKINIST in combination, tell your
healthcare provider if you:
• have had bleeding problems or blood clots
• have heart problems
• have eye problems
• have lung or breathing problems
• have high blood pressure (hypertension)
• have liver or kidney problems
• have diabetes
• plan to have surgery, dental, or other medical procedures
• have a deficiency of the G6PD enzyme
• have any other medical conditions
• are pregnant or plan to become pregnant
• are breastfeeding or plan to breastfeed
12
Please see accompanying full Prescribing Information for TAFINLAR, including
Medication Guide, and full Prescribing Information for MEKINIST, including
Patient Information Leaflet.
Tell your healthcare provider about all the medicines you take,
including prescription and over-the-counter medicines, vitamins, and herbal
supplements. TAFINLAR and certain other medicines can affect each other,
causing side effects. TAFINLAR may affect the way other medicines work, and
other medicines may affect how TAFINLAR works. You can ask your pharmacist
for a list of medicines that may interact with TAFINLAR.
Know the medicines you take. Keep a list of them to show your healthcare
provider and pharmacist when you get a new medicine.
Please read the Medication Guide for TAFINLAR and the Patient Information
Leaflet for MEKINIST, and discuss any questions you have with your healthcare
provider.
Call your doctor for medical advice about side effects. You may report side effects
to the FDA at 1-800-FDA-1088. You may also report side effects to
GlaxoSmithKline at 1-888-825-5249.
13
GETTING STARTED (cont’d)
What should I tell my
healthcare provider before
starting treatment?
Before you begin taking TAFINLAR + MEKINIST in
combination, tell your healthcare provider if you:
Tell your healthcare provider about all the
medications you take
• Have had bleeding problems or blood clots
Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.
TAFINLAR and certain other medicines can affect each other, causing side effects.
TAFINLAR may affect the way other medicines work, and other medicines may
affect how TAFINLAR works. You can ask your pharmacist for a list of medicines
that may interact with TAFINLAR.
• Have heart problems
• Have eye problems
• Have lung or breathing problems
• Have high blood pressure (hypertension)
• Have liver or kidney problems
• Have diabetes
• Plan to have surgery, dental, or other medical procedures
• Have a deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme
• Have any other medical conditions
• Are pregnant or plan to become pregnant
Keep a list of any medications you take, and
make sure your healthcare providers are aware
of any changes to any of your medicines.
• Are breastfeeding or plan to breastfeed
14
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
15
TAKING YOUR MEDICINES
How should I take TAFINLAR
+ MEKINIST in combination?
TAFINLAR is a capsule and MEKINIST is a tablet, and both are taken by mouth.
Planning and remembering when to take TAFINLAR + MEKINIST in combination
is a key part of your treatment.
When to take TAFINLAR + MEKINIST
When taking TAFINLAR + MEKINIST in combination, take the first dose of
TAFINLAR (150 mg) in the morning, and take the second dose of TAFINLAR (150 mg)
in the evening, about 12 hours later. Take MEKINIST (2 mg) only once a day, at the
same time each day, either with the morning or evening dose of TAFINLAR.
Second dose: PM
12
hours
later
150 mg
2 mg
150 mg
NOTE: This is an example of one way to take TAFINLAR and MEKINIST in combination.
Example of how to take TAFINLAR + MEKINIST
Taking your medicines
With so much on your mind, remembering to take TAFINLAR + MEKINIST in
combination every day can be hard to do. But it’s important that you understand
and follow your healthcare providers’ directions for taking TAFINLAR + MEKINIST.
Do not change your dose or stop TAFINLAR or MEKINIST unless your healthcare
provider tells you to.
First dose: AM
Develop a routine that fits your daily schedule. For example, you can take
TAFINLAR and MEKINIST in the morning at 8 AM, 1 hour before breakfast, and
then TAFINLAR again in the evening at 8 PM, at least 2 hours after dinner.
Dose adjustments of TAFINLAR + MEKINIST
If you experience side effects, your healthcare provider may decide to adjust your
dose or stop treatment with TAFINLAR + MEKINIST in combination.
Take both TAFINLAR and MEKINIST at least 1 hour before or 2 hours after a meal.
Do not open, crush, or break TAFINLAR capsules.
If you miss a dose of TAFINLAR or MEKINIST, take it as soon as you remember.
But if you miss TAFINLAR and it is within 6 hours of your next scheduled dose,
or if you miss MEKINIST and it is within 12 hours of your next scheduled dose,
just take your next dose at the regular time. Do not make up for the missed dose.
Plan your daily routine for taking TAFINLAR +
MEKINIST in combination, and do your best to
stick to that schedule.
If you take too much TAFINLAR or MEKINIST, call your healthcare provider or
go to the nearest hospital emergency room right away.
16
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
17
TAKING YOUR MEDICINES (cont’d)
• Store TAFINLAR at room temperature, between 68°F to 77°F
(20°C to 25°C).
Tips to help you remember
to take TAFINLAR + MEKINIST
Storing MEKINIST
Keep your medicine in a place where you will see it.
• Store MEKINIST in the refrigerator between 36°F to 46°F
(2°C to 8°C). Do not freeze.
Make taking medicine part of your daily routine by including it with other
activities you do every day.
• Keep MEKINIST dry and away from moisture and light.
• The bottle of MEKINIST contains a packet that helps keep your medicine dry.
Do not throw away this packet.
Create reminder systems, such as setting an alarm or timer, to remind you when
to take your medicine. Consider reminders that work best for you, such as on
your computer, cell phone, or sticky notes.
• Keep MEKINIST in its original bottle. Do not place tablets in a pill box.
Always refill your prescriptions on time, so you don’t run out of your medicine.
Storing TAFINLAR
• Safely throw away MEKINIST that is out of date or no longer needed.
Keep TAFINLAR, MEKINIST, and all medicine out of the reach
of children.
Remember that TAFINLAR and MEKINIST are
stored at different temperatures. TAFINLAR should
be kept at room temperature, while MEKINIST
must be refrigerated.
18
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
19
SIDE EFFECTS TIPS
What are some tips that
may help me with certain
side effects?
Rash
While taking TAFINLAR + MEKINIST in combination, you may experience side
effects. Some of them may be symptoms of a more serious problem, so be sure to
tell your doctor right away. Some may have an impact on your daily activities, which
may make it difficult to stick to your treatment plan. You may think skipping a
dose of TAFINLAR or MEKINIST or stopping them altogether is a way of dealing
with the side effects. But it is important that you continue to take TAFINLAR +
MEKINIST exactly as your healthcare provider prescribed. It’s also important to
keep track of these side effects and discuss them with your healthcare provider.
Rash and other skin reactions are common side effects of TAFINLAR when
used in combination with MEKINIST. In some cases these rashes and other skin
reactions can be severe, and may need to be treated in a hospital. Call your
healthcare provider if you get any of the following symptoms: skin rash that
bothers you or does not go away, acne, redness, swelling, peeling, tenderness
of hands or feet, or skin redness.
If you experience any side effects, talk with your healthcare provider
about prescriptions or over-the-counter medicines that may help you.
• Avoiding the use of hot water when bathing, showering, or washing hands
If you have any of the following side effects, tell your healthcare provider:
• Using sunscreen and avoiding unnecessary sun exposure
Fever
• Limiting long baths
• Wearing clothing that is loose, lightweight, and doesn’t rub against your skin
• Using a topical steroid and/or topical antibiotic ointment
• Using a thick, alcohol-free, soothing cream on dry areas of the body at
least twice daily
Side effects tips
When taking TAFINLAR, in combination with MEKINIST, fever may happen often
or may be severe. In some cases, chills or shaking chills, too much fluid loss
(dehydration), low blood pressure, dizziness, or kidney problems may happen
with the fever. Call your healthcare provider right away if you get a fever while
taking TAFINLAR.
Discuss the following with your healthcare provider:
• Using gentle cleansers without fragrance, alcohol, or dye
Discuss the following with your healthcare provider:
• Taking over-the-counter anti-fever medicines, such as acetaminophen or ibuprofen
20
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
21
SIDE EFFECTS TIPS (cont’d)
Headache
Diarrhea
TAFINLAR + MEKINIST can cause headaches. Tell your healthcare provider if you
have any headaches while taking TAFINLAR + MEKINIST.
Diarrhea is defined as frequent and watery bowel movements.
Discuss the following with your healthcare provider:
• Eating only bland foods
• Taking over-the-counter pain relievers, such as acetaminophen or ibuprofen,
which may help relieve headache
• Drinking plenty of water
• Eating well, getting enough sleep, and reducing your stress, which may help
moderate the number and severity of headaches
• Eating potassium-rich foods such as bananas or potatoes, without the skin
Joint aches
TAFINLAR + MEKINIST can cause joint pain. Tell your healthcare provider if you
have joint pain while taking TAFINLAR + MEKINIST.
Discuss the following with your healthcare provider:
• Eating eggs, meats (baked, without the skin), such as chicken or turkey, or fish
• Avoiding greasy foods, spicy foods, caffeine, alcohol, and raw fruit
• Avoiding products containing dairy (milk, cheese, sour cream, etc)
Call your healthcare provider for medical advice about side effects. You may report
side effects to FDA at 1-800-FDA-1088, or to GSK at 1-888-825-5249.
Discuss the following with your healthcare provider:
• Taking over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs),
which may help relieve pain and swelling
• Applying ice packs to the affected area for 15 to 20 minutes at a time,
several times a day
• Resting the affected area
Swelling of the face, arms, or legs
Talk to your healthcare provider if you notice any swelling in your face, arms, or legs.
Discuss the following with your healthcare provider:
• Dressing for comfort, including wearing loose clothing and shoes that are
not too tight
• Raising your feet when sitting or lying down and avoiding being on your
feet for too long
• Avoiding salty foods such as chips, bacon, ham, or canned soups
22
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
23
SIDE EFFECTS TIPS (cont’d)
Low
Use a side effects calendar to keep a record of how you’re feeling each day. This
can be very helpful for healthcare providers when discussing your medicine. You
can make copies of this to use throughout treatment.
Week of
Monday
Tuesday
Medium
1. In the first column, record the date
2. Record the symptom and the severity using this scale
3. Write the dose of medicine taken
4. Mark when you experienced the side effect (AM/PM)
5. In the “Notes” row, record your healthcare provider’s
recommendations and how well they worked
Keeping track of side effects
Sunday
1 2 3
Directions
Side effects calendar
Wednesday
Thursday
Friday
High
Saturday
Symptom
Dose
AM/PM
Week of
Notes
Symptom
Dose
AM/PM
Notes
Week of
Symptom
Dose
AM/PM
Week of
Notes
Symptom
Dose
AM/PM
Notes
Sample entry
k of
24
Monday
Symptom
Rash, 2
Dose
150 mg TAF, 2 mg MEK
AM/PM
k of
Sunday
v
v
Tuesday
Wednesday
Thursday
Friday
Saturday
1 2 3
Low
Medium
High
discussed with doctor,
using moisturizer
Notes
Symptom
Please
Dose see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
AM/PM
full
Prescribing Information for MEKINIST, including Patient Information
Leaflet,
Notes in back pocket.
25
RESOURCES
Partnering with your
healthcare team
Your healthcare providers can be a great source of support, in a variety of ways.
Talk openly and ask questions during all visits, and encourage your friends, loved
ones, and caregivers to do the same.
Important questions to ask your healthcare provider
about TAFINLAR + MEKINIST
What should I know before I take TAFINLAR and MEKINIST?
How can I tell if TAFINLAR and MEKINIST are working?
How should I take TAFINLAR and MEKINIST?
What is the most important information I should know about TAFINLAR
and MEKINIST?
What are the possible side effects of TAFINLAR and MEKINIST?
What can I do to help manage side effects?
How do I refill my prescription for TAFINLAR and MEKINIST?
What are some medications that may interact with TAFINLAR and MEKINIST?
How should I store TAFINLAR and MEKINIST?
Patient support resources
Commitment to Access®
GlaxoSmithKline is committed to helping patients, caregivers, and healthcare
providers gain access to GSK oncology medications. Our Commitment to Access®
program offers useful information, resources, and guidance—all in one
convenient location.
For more information about this program, please call 1-866-265-6491 or
visit gskcta.com.
Insurance coverage
GSK understands that health insurance systems can be complex. Our counselors
can help you better understand your insurance coverage and answer other
insurance-related questions that you may have.
Co-pay assistance
GSK can help you determine if you are eligible for co-pay through the GSK Co-pay
Assistance Program (for patients with commercial insurance only), or through an
independent co-pay foundation (for patients with all types of insurance).
General questions for your healthcare provider
How often should I come in for visits?
What is the best way to contact you at night, on weekends, and on holidays?
Will I need to adjust my daily activities?
Use the notes pages (32-33) to write down any other questions you want to ask
your healthcare provider
Resources
26
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
27
RESOURCES (cont’d)
Commitment to Access® (cont’d)
Free medicine assistance
GSK offers free TAFINLAR + MEKINIST to support patients with income limitations.
Patients may be eligible if they are uninsured or have generic-only prescription
coverage. Assistance through Commitment to Access ® requires enrollment by a
registered advocate.
Home delivery
GSK can help locate a network specialty pharmacy with the lowest co-pay for
TAFINLAR + MEKINIST. Learn how GSK will work with a specialty pharmacy to
deliver medicine right to your home.
Contact us
GSK Commitment to Access® counselors are available to assist you from
8:30 AM to 8:00 PM EST.
1-866-265-6491
www.gskcta.com
GSK for you
http://www.gskforyou.com
Information about metastatic melanoma
National Comprehensive Cancer Network (NCCN) Guidelines for
Patients with Melanoma
http://www.nccn.org/patients/guidelines/melanoma/index.html
AIM at Melanoma
http://www.aimatmelanoma.org
Melanoma International Foundation
http://www.melanomaintl.org
American Academy of Dermatology
http://www.aad.org
http://www.skincarephysicians.com/skincancernet
Skin Cancer Foundation
http://www.skincancer.org
The organizations and Web sites listed here are external to GSK. GSK does not have
control over the information provided on these Web sites, and therefore cannot
guarantee their accuracy and completeness. Any information you receive from these
sites should not replace the medical advice from your healthcare provider.
Many organizations offer support and information for people with cancer.
Some of the Web sites listed here provide information about health insurance
issues, treatment options, and support programs available for people with
metastatic melanoma.
National Cancer Institute
http://www.cancer.gov/cancertopics/types/melanoma
Melanoma Research Foundation (MRF)
http://www.melanoma.org
28
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
29
RESOURCES (cont’d)
General Information
about TAFINLAR + MEKINIST
in combination
Medicines are sometimes prescribed for purposes other than those listed in this
patient education brochure or in the Medication Guide. Do not use TAFINLAR +
MEKINIST in combination for a condition for which it was not prescribed. Do not
give TAFINLAR or MEKINIST to other people, even if they have the same
symptoms that you have. It may harm them.
If you would like more information, talk with your healthcare providers. You can
ask your healthcare provider for information about TAFINLAR + MEKINIST in
combination that is written for healthcare professionals. For more information,
call GlaxoSmithKline at 1-888-825-5249.
Glossary
BRAF gene: A gene that makes a protein called B-RAF, which sends signals
related to cell growth. When this gene is mutated (changed), it causes a change
in the B-RAF protein, which can increase the growth and spread of cancer cells.
DNA: Also called deoxyribonucleic acid, it is molecules inside cells that carry
genetic information and pass it from one generation to the next.
Gene: A gene is a piece of DNA, usually containing the information to make a
specific protein.
Melanocyte: A cell that makes the pigment melanin. These cells are where
melanoma begins.
Melanoma: A type of cancer beginning in the melanocytes.
Metastatic: Having to do with metastasis, the spread of cancer from the place
where it started to other places in the body.
NSAID (nonsteroidal anti-inflammatory drug): A drug used to decrease
fever, swelling, pain, and redness.
30
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and
full Prescribing Information for MEKINIST, including Patient Information
Leaflet, in back pocket.
31
EMBRACE
Support
UNDERSTAND YOUR
Treatment
For more information and resources,
call GSK at 1-888-825-5249.
Please see Important Safety Information on pages 6-13 and accompanying
full Prescribing Information for TAFINLAR, including Medication Guide, and full
Prescribing Information for MEKINIST, including Patient Information Leaflet, in
back pocket.
TAFINLAR and MEKINIST are registered trademarks of the GSK group of companies.
© 2014 GSK group of companies.
All rights reserved. Printed in USA. MEL158R0 June 2014

Download Report